JP2022547809A5 - - Google Patents
Info
- Publication number
- JP2022547809A5 JP2022547809A5 JP2022510984A JP2022510984A JP2022547809A5 JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5 JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022510984 A JP2022510984 A JP 2022510984A JP 2022547809 A5 JP2022547809 A5 JP 2022547809A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cell
- acid sequence
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962889519P | 2019-08-20 | 2019-08-20 | |
| US62/889,519 | 2019-08-20 | ||
| PCT/US2020/047071 WO2021034976A1 (en) | 2019-08-20 | 2020-08-19 | T-cell immunotherapy specific for wt-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547809A JP2022547809A (ja) | 2022-11-16 |
| JP2022547809A5 true JP2022547809A5 (enExample) | 2023-08-29 |
| JP7737978B2 JP7737978B2 (ja) | 2025-09-11 |
Family
ID=72473955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022510984A Active JP7737978B2 (ja) | 2019-08-20 | 2020-08-19 | Ｗｔ－１に特異的なｔ細胞免疫療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220409661A1 (enExample) |
| EP (1) | EP4017872A1 (enExample) |
| JP (1) | JP7737978B2 (enExample) |
| KR (1) | KR20220050176A (enExample) |
| CN (1) | CN114555790B (enExample) |
| AU (1) | AU2020334064A1 (enExample) |
| CA (1) | CA3147717A1 (enExample) |
| IL (1) | IL290609A (enExample) |
| WO (1) | WO2021034976A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202406990D0 (en) * | 2024-05-16 | 2024-07-03 | Univ Oxford Innovation Ltd | T cell receptors and uses thereof |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| AU2003215869B2 (en) | 2002-03-15 | 2008-04-24 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| WO2004024175A1 (ja) | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| PT1731605E (pt) | 2004-03-31 | 2010-04-14 | Int Inst Cancer Immunology Inc | Péptidos antigénicos de cancro derivados de wt1 |
| JP2008527001A (ja) | 2005-01-13 | 2008-07-24 | ザ ジョンズ ホプキンス ユニバーシティー | 前立腺幹細胞抗原ワクチンおよびその使用 |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| CA2894879A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| KR102415259B1 (ko) * | 2013-11-22 | 2022-06-30 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 조작된 고-친화도의 인간 t 세포 수용체 |
| US11390921B2 (en) * | 2014-04-01 | 2022-07-19 | Adaptive Biotechnologies Corporation | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) |
| ES2841274T3 (es) * | 2014-08-04 | 2021-07-07 | Hutchinson Fred Cancer Res | Inmunoterapia con células T específica para WT-1 |
| WO2016040724A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| DK3653221T5 (da) | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| JP2019515656A (ja) * | 2016-03-15 | 2019-06-13 | キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ | キメラ抗原受容体 |
| CN109996868A (zh) | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| WO2019178427A1 (en) | 2018-03-14 | 2019-09-19 | Arbor Biotechnologies, Inc. | Novel crispr dna targeting enzymes and systems |
-
2020
- 2020-08-19 JP JP2022510984A patent/JP7737978B2/ja active Active
- 2020-08-19 AU AU2020334064A patent/AU2020334064A1/en active Pending
- 2020-08-19 CN CN202080071763.9A patent/CN114555790B/zh active Active
- 2020-08-19 US US17/636,314 patent/US20220409661A1/en active Pending
- 2020-08-19 CA CA3147717A patent/CA3147717A1/en active Pending
- 2020-08-19 EP EP20771665.5A patent/EP4017872A1/en not_active Withdrawn
- 2020-08-19 WO PCT/US2020/047071 patent/WO2021034976A1/en not_active Ceased
- 2020-08-19 KR KR1020227009102A patent/KR20220050176A/ko not_active Ceased
-
2022
- 2022-02-14 IL IL290609A patent/IL290609A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932700B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| Marofi et al. | CAR‐NK cell in cancer immunotherapy; A promising frontier | |
| JP2024074801A5 (enExample) | ||
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Fan et al. | Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia | |
| JP2017523784A5 (enExample) | ||
| US11970545B2 (en) | T cell-antigen coupler with Y182T mutation and methods of uses thereof | |
| US10654934B2 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| JP2017531687A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2021512637A5 (enExample) | ||
| JP2022527267A5 (enExample) | ||
| JP2022525099A5 (enExample) | ||
| BR112021000735A2 (pt) | acoplador de antígeno de células t com várias otimizações de construto | |
| JP2022523971A5 (enExample) | ||
| JP2022523553A5 (enExample) | ||
| JP2022547809A5 (enExample) | ||
| JP2021525067A5 (enExample) | ||
| WO2018064921A1 (en) | Use of chimeric antigen receptor modified cells to treat cancer | |
| JP2022543059A5 (enExample) | ||
| Hanagiri et al. | Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes | |
| JP2022543058A5 (enExample) | ||
| Smith et al. | Immunotherapy of colorectal cancer | |
| JP2022543060A5 (enExample) | ||
| Smith Jr et al. | Targeting cancer with genetically engineered TCR T cells |